Erratum: Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B (Hepatology International (2010) 4 (414-422) DOI: 10.1007/s12072-009-9162-x);Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B

Hepatology International

Volumn 4, Issue 1, 2010, Pages 414-422

  Karino, Yoshiyasu ^a   Toyota, Joji ^a   Kumada, Hiromitsu ^b   Katano, Yoshiaki ^c   Izumi, Namiki ^d   Kobashi, Haruhiko ^e   Sata, Michio ^f   Moriyama, Mitsuhiko ^g   Imazeki, Fumio ^h   Kage, Masayoshi ^f   Ishikawa, Hiroki ⁱ   Masaki, Nobuyuki ⁱ   Seriu, Taku ⁱ   Omata, Masao ^j  

^a Sapporo Kosei General Hospital   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d MUSASHINO RED CROSS HOSPITAL   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h CHIBA UNIVERSITY   (Japan)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Chronic hepatitis B; Entecavir; Japanese; Lamivudine refractory; Lamivudine resistant

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACKACHE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; JAPANESE; LIVER FIBROSIS; LIVER HISTOLOGY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77949655510     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-010-9224-0     Document Type: Erratum

References (51)

1. D Lavanchy 2004 Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 97 107 10.1046/j.1365-2893.2003.00487.x 1:STN:280: DC%2BD2c7gs1Whug%3D%3D 14996343 (Pubitemid 38365759)
2. WM Lee 1997 Hepatitis B virus infection N Engl J Med 337 1733 1745 10.1056/NEJM199712113372406 1:STN:280:DyaK1c%2FktFyjtA%3D%3D 9392700 (Pubitemid 27527771)
3. World Health Organization. Hepatitis B Fact Sheet WHO/204. Geneva: World Health Organization; 2000 [cited 2008 June 30]. http://www.who.int/mediacentre/ factsheets/fs204/en/.
4. I Merican R Guan D Amarapuka MJ Alexander A Chutaputti RN Chien, et al. 2000 Chronic hepatitis B virus infection in Asian countries J Gastroenterol Hepatol 15 1356 1361 10.1046/j.1440-1746.2000.0150121356.x 1:STN:280: DC%2BD3M7jvFCitw%3D%3D 11197043 (Pubitemid 32052906)
5. S Usuda H Okamoto H Iwanari K Baba F Tsuda Y Miyakawa, et al. 1999 Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the pre S2-region product J Virol Methods 80 97 112 10.1016/S0166-0934(99)00039-7 1:CAS:528:DyaK1MXjsVSht7s%3D 10403681 (Pubitemid 29248907)
6. J Hou X Liu F Gu 2005 Epidemiology and prevention of hepatitis B virus infection Int J Med Sci 2 50 57 15968340
7. E Orito M Mizokami H Sakugawa K Michitaka K Ishikawa T Ichida, et al. 2001 A case-control study of clinical and molecular biological differences between hepatitis B viruses of genotypes B and C Hepatology 33 218 223 10.1053/jhep.2001.20532 1:CAS:528:DC%2BD3MXktFajsA%3D%3D 11124839 (Pubitemid 32016905)
8. JW Jang YC Lee MS Kim SY Lee SH Bae JY Choi, et al. 2007 A 13-year longitudinal study of the impact of double mutations in the core promoter region of hepatitis B virus on HBeAg seroconversion and disease progression in patients with genotype C chronic active hepatitis J Viral Hepat 14 169 175 10.1111/j.1365-2893.2006.00788.x 1:STN:280:DC%2BD2s7gvVOhuw%3D%3D 17305882 (Pubitemid 46257182)
9. MW Yu SH Yeh PJ Chen YF Liaw CL Lin CJ Liu, et al. 2005 Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men J Natl Cancer Inst 97 265 272 1:CAS:528:DC%2BD2MXhsFSns78%3D 15713961
10. E Orito M Mizokami 2007 Differences of HBV genotypes and hepatocellular carcinoma in Asian countries Hepatol Res 37 Suppl 1 S33 S35 10.1111/j.1872-034X. 2007.00101.x 1:CAS:528:DC%2BD1cXkt1Ojt7Y%3D 17627633 (Pubitemid 47086513)
11. HLY Chan AY Hui ML Wong Tse Am LC Hung VW Wong, et al. 2004 Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma Gut 53 1494 1498 10.1136/gut.2003.033324 15361502 (Pubitemid 39265273)
12. UH Iloeje HI Yang J Su CL Jen SL You CJ Chen Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group 2006 Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 678 686 10.1053/j.gastro.2005.11.016 16530509 (Pubitemid 43374518)
13. CJ Chen HI Yang J Su CL Jen SL You SN Lu REVEAL-HBV Study Group, et al. 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 65 73 10.1001/jama.295.1.65 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D 16391218 (Pubitemid 43042691)
14. MF Yuen HJ Yuan DK Wong JC Yuen WM Wong AO Chan, et al. 2005 Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications Gut 54 1610 1614 10.1136/gut.2005.065136 15871997 (Pubitemid 41531781)
15. YF Liaw JJ Sung WC Chow G Farrell CZ Lee H Yuen Cirrhosis Asian Lamivudine Multicentre Study Group 2004 Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 1521 1531 10.1056/NEJMoa033364 1:CAS:528:DC%2BD2cXot1Kls7w%3D 15470215 (Pubitemid 39315319)
16. JL Dienstag ER Schiff TL Wright RP Perrillo HW Hann Z Goodman, et al. 1999 Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1256 1263 10.1056/NEJM199910213411702 1:CAS:528:DyaK1MXnt1Cqs78%3D 10528035 (Pubitemid 29489740)
17. CL Lai RN Chien NW Leung TT Chang R Guan DI Tai, et al. 1998 A one-year trial of lamivudine for chronic hepatitis B N Engl J Med 339 61 68 10.1056/NEJM199807093390201 1:CAS:528:DyaK1cXkvVSqtbY%3D 9654535 (Pubitemid 28304879)
18. AS Lok CL Lai N Leung GB Yao ZY Cui ER Schiff, et al. 2003 Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 1714 1722 10.1053/j.gastro.2003.09.033 1:CAS:528: DC%2BD2cXhtVOrug%3D%3D 14724824 (Pubitemid 37500436)
19. JL Dienstag RD Goldin EJ Heathcote HW Hann M Woessner SL Stephenson, et al. 2003 Histological outcome during long-term lamivudine therapy Gastroenterology 124 105 117 10.1053/gast.2003.50013 1:CAS:528: DC%2BD3sXot1antQ%3D%3D 12512035 (Pubitemid 36055344)
20. TT Chang CL Lai RN Chien R Guan SG Lim CM Lee, et al. 2004 Four years of lamivudine treatment in Chinese patients with chronic hepatitis B J Gastroenterol Hepatol 19 1276 1282 10.1111/j.1440-1746.2004.03428.x 1:CAS:528:DC%2BD2cXhtVKnt7vJ 15482535 (Pubitemid 39481762)
21. CL Lai J Dienstag E Schiff NW Leung M Atkins C Hunt, et al. 2003 Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Clin Infect Dis 36 687 696 10.1086/368083 1:CAS:528:DC%2BD3sXjtVKqtbk%3D 12627352 (Pubitemid 36337972)
22. GV Papatheodoridis E Dimou A Laras V Papadimitropoulos SJ Hadziyannis 2002 Course of virologic breakthrough under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease Hepatology 36 219 226 10.1053/jhep.2002.33894 12085368 (Pubitemid 34700781)
23. V Di Marco A Marzano P Lampertico P Andreone T Santantonio PL Almasio Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy, et al. 2004 Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine Hepatology 40 883 891 10.1002/hep.1840400418 1:CAS:528:DC%2BD2cXptV2qt7Y%3D 15382125
24. P Andreone A Gramenzi C Cursaro M Biselli C Cammà F Trevisani, et al. 2004 High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance J Viral Hepat 11 439 442 10.1111/j.1365-2893.2004.00564.x 1:STN:280:DC%2BD2cvltVOgtQ%3D%3D 15357649 (Pubitemid 39336225)
25. ASF Lok BJ McMahon 2007 Chronic hepatitis B Hepatology 45 507 539 10.1002/hep.21513 1:CAS:528:DC%2BD2sXisVKns7o%3D 17256718 (Pubitemid 46374607)
26. TT Chang RG Gish R de Man A Gadano J Sollano YC Chao BEHoLD AI463022 Study Group, et al. 2006 A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 1001 1010 10.1056/NEJMoa051285 1:CAS:528:DC%2BD28XitFWms7Y%3D 16525137 (Pubitemid 43357804)
27. CL Lai D Shouval AS Lok CL Lai D Shouval AS Lok BEHoLD AI463027 Study Group, et al. 2006 Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 1011 1020 10.1056/NEJMoa051287 1:CAS:528:DC%2BD28XitFWlsrY%3D 16525138 (Pubitemid 43357805)
28. M Sherman C Yurdaydin J Sollano M Silva YF Liaw J Cianciara AI463026 BEHoLD Study Group 2006 Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B Gastroenterology 130 2039 2049 10.1053/j.gastro.2006.04.007 1:CAS:528:DC%2BD28XntVWitrw%3D 16762627 (Pubitemid 43816960)
29. TT Chang RG Gish SJ Hadziyannis J Cianciara M Rizetto ER Schiff BEHoLD Study Group, et al. 2005 A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients Gastroenterology 129 1198 1209 10.1053/j.gastro.2005.06.055 1:CAS:528: DC%2BD2MXhtFyltb%2FJ 16230074 (Pubitemid 41446860)
30. M Sherman C Yurdaydin H Simsek M Silva YF Liaw VK Rustgi AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group, et al. 2008 Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical and serology outcomes through 96 weeks Hepatology 48 99 108 10.1002/hep.22323 1:CAS:528:DC%2BD1cXptFemtbc%3D 18537189
31. RG Gish AS Lok TT Chang RA de Man A Gadano J Sollano, et al. 2007 Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B Gastroenterology 133 1437 1444 10.1053/j.gastro.2007.08.025 1:CAS:528:DC%2BD2sXhsVGqtr%2FI 17983800 (Pubitemid 350029745)
32. F Suzuki J Toyoda Y Katano M Sata M Moriyama F Imazeki, et al. 2008 Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients J Gastroenterol Hepatol 23 9 1320 1326 10.1111/j.1440-1746.2008.05455.x 1:CAS:528: DC%2BD1cXht1Cls7jL 18554238
33. RG Knodell KG Ishak WC Black TS Chen R Craig N Kaplowitz, et al. 1981 Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1 431 435 10.1002/hep.1840010511 1:STN:280:DyaL38%2FnsVagsA%3D%3D 7308988
34. F Ichida T Tsuji M Omata T Ichida K Inoue T Kamimura, et al. 1996 New Inuyama classification: new criteria for histological assessment of chronic hepatitis Int Hepatol Commun 6 112 119 10.1016/S0928-4346(96)00325-8 (Pubitemid 27059904)
35. O Yokosuka H Kumada J Toyota K Takaguchi H Kobashi M Shindo, et al. 2008 Three-year assessment of entecavir (ETV) resistance in nucleoside-naïve and lamivudine (LVD) refractory Japanese patients with chronic hepatitis B (CHB) Hepatol Int 2 A161 Abstract No.: FP067
36. T Nakayoshi T Maeshiro T Nakayoshi H Nakasone H Sakugawa F Kinjo, et al. 2003 Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa Islands: a prospective study J Med Virol 70 350 354 10.1002/jmv.10270 12766996 (Pubitemid 36638046)
37. TN Duong N Horiike K Michitaka C Yan M Mizokami Y Tanaka, et al. 2004 Comparison of genotypes C and D of the hepatitis B virus in Japan: a clinical and molecular biological study J Med Virol 72 551 557 10.1002/jmv.20044 1:CAS:528:DC%2BD2cXislyktro%3D 14981757 (Pubitemid 38296066)
38. JH Kao NH Wu PJ Chen MY Lai DS Chen 2000 Hepatitis B genotypes and the response to interferon therapy J Hepatol 33 998 1002 10.1016/S0168-8278(00) 80135-X 1:CAS:528:DC%2BD3cXovVKjsbg%3D 11131465
39. YF Liaw N Leung JH Kao T Piratvisuth E Gane KH Han the Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver, et al. 2008 Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 263 283 10.1007/s12072-008- 9080-3 19669255
40. H Mommeja-Marin E Mondou MR Blum F Rousseau 2003 Serum HBV DNA as a marker of efficacy during therapy for CHB infection: analysis and review of the literature Hepatology 37 1309 1319 10.1053/jhep.2003.50208 12774009 (Pubitemid 36667310)
41. YF Liaw RN Chien CT Yeh 2004 No benefit to continue lamivudine therapy after emergence of YMDD mutations Antivir Ther 9 257 262 1:CAS:528: DC%2BD2cXltFyhs7g%3D 15134188
42. MG Peters H Hann Hw P Martin EJ Heathcote P Buggisch R Rubin, et al. 2004 Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 91 101 10.1053/j.gastro.2003.10.051 1:CAS:528:DC%2BD2cXhtFGntLo%3D 14699491 (Pubitemid 38040727)
43. SK Fung HB Chae RJ Fontana H Conjeevaram J Marrero K Oberhelman, et al. 2006 Virologic response and resistance to adefovir in patients with chronic hepatitis B J Hepatol 44 283 290 10.1016/j.jhep.2005.10.018 1:CAS:528: DC%2BD28Xktl2qsA%3D%3D 16338024 (Pubitemid 43069209)
44. YS Lee DJ Suh YS Lim SW Jung KM Kim HC Lee, et al. 2006 Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy Hepatology 43 1385 1391 10.1002/hep.21189 1:CAS:528:DC%2BD28XmsF2msr8%3D 16729316 (Pubitemid 43980117)
45. SK Fung P Andreone SH Han K Rajender Reddy A Regev EB Keeffe, et al. 2005 Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation J Hepatol 43 937 943 10.1016/j.jhep.2005.05.037 1:CAS:528:DC%2BD2MXht1egsrnP 16168522 (Pubitemid 41627977)
46. I Rapti E Dimou P Mitsoula SJ Hadziyannis 2007 Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B Hepatology 45 307 313 10.1002/hep.21534 1:CAS:528: DC%2BD2sXisVKgu70%3D 17256746 (Pubitemid 46374587)
47. P Lampertico M Vigano E Manenti M Iavarone G Lunghi M Colombo 2005 Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine Hepatology 42 1414 1419 10.1002/hep.20939 1:CAS:528:DC%2BD2MXhtlGns7vP 16317671 (Pubitemid 43260045)
48. P Lampertico A Marzano M Levrero T Santantonio V Di Marco M Brunetto, et al. 2007 Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B J Hepatol 46 Suppl 1 S191 10.1016/S0168-8278(07)62100-X
49. DJ Tenney RE Rose CJ Baldick KA Pokornowski BJ Eggers J Fang, et al. 2009 Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy Hepatology 49 1503 1514 10.1002/hep.22841 1:CAS:528:DC%2BD1MXlslKmurw%3D 19280622
50. RJ Colonno R Rose CJ Baldick S Levine K Pokornowski CF Yu, et al. 2006 Entecavir resistance is rare in nucleoside-naïve patients with hepatitis B Hepatology 44 1656 1665 10.1002/hep.21422 1:CAS:528:DC%2BD2sXislOjtg%3D%3D 17133475
51. CJ Baldick DJ Tenney CE Mazzucco BJ Eggers RE Rose KA Pokornowski, et al. 2008 Comprehensive evaluation of hepatitis B reverse transcriptase substitutions associated with entecavir resistance Hepatology 47 1473 1482 10.1002/hep.22211 1:CAS:528:DC%2BD1cXmvVChsr4%3D 18435459